group MITO "Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies" The Association is a non-profit organization, and aims to bring together lovers of Gynecologic Oncology in order to promote progress in the clinical, experimental, and social welfare, to foster relations between the gynecology oncology specialists, general practitioners and specialists in other disciplines, to establish scientific relations with similar associations and Italian and foreign institutional organizations to participate in national, regional and local. The Association also aims to promote experimental and clinical research, the quality of cancer care through the preparation of Guidelines for the surgical and medical therapy cancer, and interdi...
Introduction: The multidisciplinary management of oncologic patients is identified as the bottom lin...
Ongoing and effective collaboration with industry, government, and patients aims to ensure that the ...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...
group MITO "Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies" The Associati...
Ovarian cancer represents one of the most aggressive female cancers in the world, remaining a tumor ...
Introduction: The multidisciplinary management of oncologic patients is identified as the bottom lin...
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Biological, physical and clinical aspects of cancer treatment with ionising radiatio
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
Aim: To briefly review history, structure, past events and future projects of AIRO (Associazione Ita...
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
Introduction: The multidisciplinary management of oncologic patients is identified as the bottom lin...
Ongoing and effective collaboration with industry, government, and patients aims to ensure that the ...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...
group MITO "Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies" The Associati...
Ovarian cancer represents one of the most aggressive female cancers in the world, remaining a tumor ...
Introduction: The multidisciplinary management of oncologic patients is identified as the bottom lin...
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Biological, physical and clinical aspects of cancer treatment with ionising radiatio
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
Aim: To briefly review history, structure, past events and future projects of AIRO (Associazione Ita...
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
In the era of personalized medicine, the introduction of translational studies in clinical trials ha...
Introduction: The multidisciplinary management of oncologic patients is identified as the bottom lin...
Ongoing and effective collaboration with industry, government, and patients aims to ensure that the ...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...